Profile data is unavailable for this security.
About the company
Henan Lingrui Pharmaceutical Co., Ltd is a China-based company, principally engaged in the research and development, production and distribution of medicines. The Company's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The Company distributes its products throughout China, with Henan Province and Beijing as its major markets.
- Revenue in CNY (TTM)3.23bn
- Net income in CNY526.17m
- Incorporated1999
- Employees2.52k
- LocationHenan Lingrui Pharmaceutical Co LtdNo.666, Jiangjun Road, Xinxian CountyXINYANG 465550ChinaCHN
- Phone+86 3 762973569
- Fax+86 3 762987888
- Websitehttp://www.lingrui.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BrightGene Bio-Medical Technology Co Ltd | 1.16bn | 233.79m | 13.09bn | 1.13k | 56.59 | 5.51 | -- | 11.29 | 0.5477 | 0.5477 | 2.73 | 5.63 | 0.2563 | 1.59 | 3.18 | 1,028,270.00 | 4.65 | 8.29 | 5.67 | 9.95 | 59.31 | 58.01 | 18.13 | 21.31 | 1.75 | 5.32 | 0.4723 | 28.99 | -3.33 | 26.28 | -1.77 | 39.18 | 54.07 | -- |
| Bio-Thera Solutions Ltd | 711.46m | -370.90m | 13.71bn | 1.17k | -- | 12.54 | -- | 19.28 | -0.8957 | -0.8957 | 1.72 | 2.64 | 0.3099 | 0.9439 | 6.06 | 609,647.70 | -16.15 | -23.62 | -23.70 | -30.81 | 71.41 | 79.76 | -52.13 | -106.72 | 0.8258 | -367.55 | 0.3515 | -- | 54.86 | -- | 17.87 | -- | -3.78 | -- |
| Mabwell Shanghai Bioscience Co Ltd | 127.84m | -1.05bn | 14.13bn | 1.49k | -- | 5.47 | -- | 110.56 | -2.64 | -2.64 | 0.3199 | 6.47 | 0.0282 | 0.0434 | 14.54 | 85,738.12 | -23.34 | -37.61 | -27.05 | -45.95 | 95.96 | 81.54 | -828.26 | -2,112.26 | 2.31 | -- | 0.3344 | -- | 361.03 | 27.88 | -10.28 | -- | 17.35 | -- |
| Henan Lingrui Pharmaceutical Co., Ltd. | 3.23bn | 526.17m | 14.43bn | 2.52k | 26.99 | 5.25 | -- | 4.47 | 0.9429 | 0.9429 | 5.83 | 4.85 | 0.7401 | 2.04 | 11.51 | 1,280,356.00 | 12.05 | 9.66 | 19.85 | 14.55 | 72.05 | 75.00 | 16.28 | 13.82 | 1.08 | -- | 0.0383 | 70.49 | 11.45 | 10.18 | 28.71 | 16.47 | -36.31 | 31.95 |
| Zhejiang Jiuzhou Pharmaceutical Co Ltd | 5.25bn | 989.32m | 14.50bn | 4.88k | 14.61 | 1.66 | -- | 2.76 | 1.10 | 1.10 | 5.84 | 9.69 | 0.4523 | 1.87 | 4.36 | 1,076,055.00 | 8.52 | 10.10 | 11.07 | 13.69 | 35.80 | 34.64 | 18.83 | 16.26 | 2.07 | -- | 0.1816 | 40.79 | 1.44 | 24.29 | 12.20 | 45.74 | 32.14 | 20.11 |
| Suzhou Zelgen Biopharmaceuticals Co Ltd | 386.57m | -260.85m | 14.59bn | 867.00 | -- | 9.15 | -- | 37.73 | -1.00 | -1.00 | 1.49 | 6.02 | 0.1621 | 0.2594 | 3.75 | 445,874.00 | -11.74 | -27.13 | -20.82 | -39.20 | 92.29 | 92.75 | -72.40 | -220.71 | 2.15 | -- | 0.3842 | -- | 27.83 | 211.81 | 39.08 | -- | 41.38 | -- |
| Shanghai Shyndec Pharmaceutical Co Ltd | 12.07bn | 691.88m | 14.59bn | 11.61k | 20.53 | 1.18 | -- | 1.21 | 0.530 | 0.530 | 9.24 | 9.24 | 0.6193 | 3.21 | 7.47 | 1,039,794.00 | 4.95 | 4.85 | 7.09 | 8.17 | 37.18 | 43.00 | 7.99 | 7.03 | 2.22 | -- | 0.1125 | 17.52 | -6.86 | 1.29 | 10.21 | -0.3897 | -2.21 | 0.00 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 1.07bn | 352.22m | 14.78bn | 965.00 | 41.96 | 2.96 | -- | 13.77 | 0.571 | 0.571 | 1.74 | 8.09 | 0.2078 | 1.14 | 9.25 | 1,112,527.00 | 6.61 | 1.32 | 6.93 | 1.41 | 77.85 | 80.74 | 31.81 | 6.55 | 6.66 | -- | 0.01 | 8.25 | 22.84 | -2.35 | 497.63 | -4.44 | 21.22 | -- |
| Liaoning Cheng Da Co Ltd | 11.18bn | 17.48m | 15.86bn | 3.36k | 797.69 | 0.5439 | -- | 1.42 | 0.013 | 0.013 | 7.34 | 19.07 | 0.2358 | 4.41 | 6.49 | 3,330,121.00 | -0.5366 | 3.59 | -0.7644 | 5.21 | 16.03 | 14.15 | -2.28 | 9.89 | 0.7792 | -- | 0.2834 | 15.93 | -25.97 | -10.97 | -80.95 | -21.26 | 7.04 | -- |
Data as of Mar 13 2024. Currency figures normalised to Henan Lingrui Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
13.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| GF Fund Management Co., Ltd.as of 30 Jun 2023 | 33.04m | 5.63% |
| First Seafront Fund Management Co., Ltd.as of 30 Jun 2023 | 13.82m | 2.36% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2023 | 10.48m | 1.79% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2023 | 6.13m | 1.05% |
| Morgan Stanley Huaxin Fund Management Co., Ltd.as of 30 Jun 2023 | 4.18m | 0.71% |
| Taikang Asset Management Co. Ltd.as of 30 Jun 2023 | 3.91m | 0.67% |
| Manulife TEDA Fund Management Co., Ltd.as of 30 Jun 2023 | 2.51m | 0.43% |
| China Asset Management Co., Ltd.as of 30 Jun 2023 | 2.35m | 0.40% |
| Huisheng Fund Management Co., Ltd.as of 30 Jun 2023 | 2.31m | 0.40% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2023 | 2.22m | 0.38% |
More ▼
Data from 30 Jun 2023 - 29 Feb 2024Source: FactSet Research Systems Inc.
